UBS AM
AMRI

UBS AM’s Albany Molecular Research Inc AMRI Stock Holding History

UBS AM’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-13,792
Closed -$228K – 2797
2016
Q3 		$228K Buy
13,792
+1,292
+10% +$19.1K ﹤0.01% 2399
2016
Q2 		$168K Hold
12,500
– – ﹤0.01% 2498
2016
Q1 		$191K Sell
12,500
-12,900
-51% -$202K ﹤0.01% 2445
2015
Q4 		$504K Sell
25,400
-1,300
-5% -$24.7K ﹤0.01% 2052
2015
Q3 		$465K Buy
26,700
+11,100
+71% +$226K ﹤0.01% 2056
2015
Q2 		$315K Buy
15,600
+4,100
+36% +$79.1K ﹤0.01% 2336
2015
Q1 		$202K Buy
11,500
+1,000
+10% +$17K ﹤0.01% 2482
2014
Q4 		$171K Buy
+10,500
New +$193K ﹤0.01% 2504

Other funds holding AMRI

PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

UBS AM's AMRI Position: Q4 2016 in Review

UBS AM sold out of Albany Molecular Research Inc (AMRI) in Q4 2016, closing a stake of 13,792 shares — an estimated $228K sold.

UBS AM first reported a position in AMRI in Q4 2014 and held it in 8 quarters. The position peaked at $504K in Q4 2015. 133 funds tracked by Wall St. Rank hold AMRI as of Q4 2016.

  • UBS AM reported no remaining Albany Molecular Research Inc position as of Q4 2016 after selling out during the quarter.
  • UBS AM sold 13,792 Albany Molecular Research Inc shares in Q4 2016, an estimated $228K.
  • UBS AM first reported a position in Albany Molecular Research Inc in Q4 2014 and held it in 8 quarters.
  • UBS AM's Albany Molecular Research Inc position peaked at $504K in Q4 2015.
  • 133 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2016.

Based on UBS AM's 13F filing for Q4 2016, filed 14 Feb 2017.